![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Divisions of Cardiovascular Medicine (J.L.S.) and Cardiothoracic Surgery (J.S., X.F., J.E.B.), Department of Pharmacology and Toxicology (A.H., G.J.G.), and Children's Research Institute (J.E.B.), Medical College of Wisconsin, Milwaukee, Wisconsin
Received October 24, 2007; accepted November 29, 2007.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
Adenosine is an endogenous nucleoside present in normal conditions; however, during ischemia, the production of adenosine increases severalfold (Shryock and Belardinelli, 1997
). Adenosine activates four well characterized G protein-coupled receptors (GPCRs) to produce various physiological effects that attenuate many of the proposed mechanisms of I/R injury (Headrick et al., 2003a). However, the specific adenosine receptor (AR) subtype (A1AR, A2aAR, A2bAR, or A3AR) responsible for adenosine-mediated cardioprotective effects remains unclear. The signaling pathway for adenosine-mediated cardioprotection involves the activation of PI3K/Akt, ERK1/2, nitric-oxide synthase (NOS), and the sarcolemmal (sarc) or mitochondrial (mito) ATP-sensitive potassium channels (KATP channels) (Headrick et al., 2003b). In experimental models as well as in small clinical studies, administration of adenosine with reperfusion results in a marked reduction in infarct size and improvement in ventricular function. In the larger AMISTAD and AMISTAD II trials, a 3-h infusion of adenosine as an adjunct to reperfusion resulted in a striking reduction in infarct size (55–65%) but did not significantly affect clinical outcome (Mahaffey et al., 1999; Ross et al., 2005). Despite these potential cardioprotective actions, adenosine treatment has not been incorporated into standard clinical practice. Adenosine has a very short half-life, necessitating a continuous infusion. Not only is this inconvenient, but it increases the chance of side effects, such as bradycardia and hypotension. Harnessing endogenous adenosine provides a novel treatment strategy to reduce I/R, which would eliminate the side effects and expense of adenosine infusions.
Thrombin contributes to I/R injury independently of its effects on platelets and fibrinogen (Chong et al., 2003; Strande et al., 2007). Thrombin activates the seven transmembrane G protein-coupled protease-activated receptors (PARs) 1 and 4 by proteolytic cleavage of the N terminus to expose a tethered ligand, which then transactivates the receptor (Ossovskaya and Bunnett, 2004). Thrombin is a nonselective activator of PARs; therefore, in experimental systems, synthetic activating peptides (APs) containing 5- to 14-amino acid residues that correspond to the tethered ligand are used to selectively activate each receptor. The peptide AYPGKF-amide is a PAR4 AP. PAR1 and PAR4 were originally detected in platelets where their activation causes platelet activation and aggregation. As a result, they have been identified in a variety of cell types and tissues and have been shown to modulate a variety of physiological processes. We have recently shown that PAR1 inhibition protects against myocardial I/R injury by recruiting cardioprotective pathways including PI3K/Akt, NOS, and KATP channels (Strande et al., 2007). However, the role of PAR4 in determining the extent of myocardial I/R injury is not known. Therefore, we focused on PAR4 in this study to determine whether PAR4 inhibition is cardioprotective.
Adenosine has been shown to modulate thrombin signaling in various models. For instance, in vein endothelial cells, adenosine is able to down-regulate tissue factor induction by thrombin (Deguchi et al., 1998). Additionally in corneal endothelium, adenosine opposes thrombin-mediated inhibition of calcium wave propagation (D'Hondt et al., 2007). However, the mechanism of this adenosine and thrombin receptor "cross-talk" is poorly understood. Furthermore, it is not known whether this receptor cross-talk occurs in the myocardium. Therefore, we proposed that by blocking thrombin activation pathways with a PAR4 antagonist, endogenous adenosine would be allowed to exert its cardioprotective effects.
We used both an in vivo rat model and an in vitro isolated rat heart model of I/R injury to assess the effects of PAR4 blockade on infarct size. The absence of blood in the isolated heart model eliminated the possible interference of coagulation as well as platelet activation in mediating injury. We studied the ability of two structurally different PAR4 inhibitors, trans-cinnamoyl-YPGKF-amide (tc-Y-NH2) and palmitoyl-SGRRYGHALR-amide (P4pal10), to protect the heart against injury from I/R. We then assessed the role of adenosine by blocking its effects with a nonselective adenosine receptor antagonist. Furthermore, based on the assumption that antagonizing PAR4 signaling would unmask AR signaling, we confirmed the signaling pathway leading to protection was similar to that previously reported for AR activation. Therefore, we explored the adenosine-mediated cardioprotective pathways including Akt, ERK1/2, NOS, sarc, and mitoKATP channels.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
PCR. Rat heart PCR Ready First Strand cDNA was purchased from BioChain Institute, Inc. (Hayward, CA). This consists of cDNA reverse transcribed from mRNA pooled from three rat hearts. Forward and reverse primers used for amplifying rat PAR4 were prepared commercially, based on published data (Rohatgi et al., 2004): sense, 5'-GGA ATG CCA GAC GCC CAG CAT C-3'; and antisense, 5'-GGT GAG GCG TTG ACC ACG CA-3' (PCR product, 559 bp). The conditions for amplification were 95°C for 10 min for one cycle, 94°C for 30 s, 64°C for 90 s, 72°C for 60 s for 40 cycles, and 72°C for 10 min for 1 cycle. One microliter of cDNA was used in each reaction along with iTaq DNA Polymerase and dNTP mix (Bio-Rad, Hercules, CA). Electrophoresis was conducted on a 1.2% agarose gel stained with SYBR Green.
Isolation of Rat Cardiac Fibroblasts and Cardiomyocytes. Cardiomyocytes from SD rats were a generous gift from Eugene Konorev (Medical College of Wisconsin, Milwaukee, WI). They were isolated according to previously published methods (Piper et al., 1990). Cardiac fibroblasts from SD rats were isolated as described previously (Dubey et al., 1997).
Immunoblot Analysis. For PAR4 protein detection, heart homogenates and immunoblot analysis were performed using methods described previously (Strande et al., 2007), and immunoblots were incubated with a 1:200 dilution of the primary antibody [PAR4 (C-20), catalog number sc-8464; Santa Cruz Biotechnology, Inc., Santa Cruz, CA]. For phosphorylated Akt and ERK1/2 detection, the following alterations were made. The free wall of the left ventricle from each group (control, tc-Y-NH2, wortmannin, and PD98059) were harvested for protein extraction either immediately after perfusion with the compound or after 30-min ischemia followed by 5 min of reperfusion. After the proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes, the membrane was blocked in 5% bovine serum albumin in Tris-buffered saline/0.1% Tween 20. Immunoblots were then incubated with a 1:1000 dilution of either phospho-Akt (Ser473) or phospho-p44/42 mitogen-activated protein kinase (Thr202/Tyr204) antibodies from Cell Signaling Technology (Danvers, MA). An antibody against β-actin (Sigma-Aldrich) or glyceraldehyde-3-phosphate dehydrogenase (Cell Signaling Technology) was used to standardize protein loading of each of the blots. A secondary antibody was then applied, followed with enhanced chemiluminescence solution (Amersham Life Science, Arlington Heights, IL), and exposed to film for 1 min.
P4pal10 and Cardioprotection Studies in Vivo. An in vivo anesthetized rat model was used for these experiments with the general surgical protocol and determination of infarct size as described previously (Peart and Gross, 2005). For infarct size studies, rats (n = 6/group) underwent 30 min of regional ischemia followed by 120 min of reperfusion. P4pal10 was administered i.v. over 1 min starting 15 min before ischemia, 15 min after the onset of ischemia, and 10 s after the onset of reperfusion in a separate series of experiments (n = 6 rats/group).
tc-Y-NH2 and Cardioprotection Studies in Vitro. Rats were anesthetized with a mixture containing pentobarbital sodium (50 mg/kg) and heparin (1000 IU/kg) i.p. Excised hearts were retrograde perfused through the aorta with a modified Krebs' buffer and instrumented as described previously (Strande et al., 2007). In brief, coronary flow rate was determined by timed collection of the coronary effluent. A saline-filled latex balloon connected to a pressure transducer was inserted into the left ventricle, and baseline end-diastolic pressure was set at 5 to 10 mm Hg. Heart rate, left ventricle enddiastolic pressure, and left ventricular developed pressures (LVDPs) were recorded continuously. The measurements for postischemic recovery of LVDP used for comparison were taken at 180 min of reperfusion. After stabilization for 15 to 20 min, the hearts (n = 6/group) were subjected to 30 min of regional ischemia, followed by 180 min of reperfusion. Group 1 received no treatment (Fig. 1A). The hearts in group 2 were perfused continuously with different concentrations of tc-Y-NH2 from 15 min before coronary occlusion until occlusion (Fig. 1B). The hearts in group 3 were continuously perfused with an inhibitor (PAR4 AP, wortmannin, PD98059, L-NMA, or glibenclamide) starting 15 min before the commencement of tc-Y-NH2 perfusion (i.e., from 15 min before ischemia) for 30 min (Fig. 1C). The hearts in group 4 were continuously perfused with an inhibitor (PAR4 AP, wortmannin, PD98059, L-NMA, or glibenclamide) starting at 30 min before occlusion (Fig. 1D). The hearts in group 5 were continuously perfused for 15 min with tc-Y-NH2 and a nonspecific AR antagonist, 8-sulfaphenyltheophylline (8-SPT) (Fig. 1E). The results from groups 1 and 2 were used for comparison in Figs. 4, 5, 6, 7, 8.
|
|
|
|
|
|
).
Statistical Analysis. Six rats/hearts were included in each group. Data reported are mean ± S.D. Statistical analysis was performed by use of repeated measures analysis of variance with the Greenhouse-Geisser adjustment used to correct for the inflated risk of a type I error (Strande et al., 2007). If significant, the Mann-Whitney test was used as a second step to identify which groups were significantly different (Strande et al., 2007). Significance was set at P < 0.05.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
), to determine whether PAR4 inhibition limited I/R injury in an in vivo rat model. We first performed a dose-response analysis (0.1–100 µg/kg) to determine the optimal protective dose. The principal endpoint of this study was infarct size, expressed as a percentage of the AAR. Infarct size was 64 ± 2% of the AAR in the control group. No significant change in infarct size was detected with the 0.1, 30, and 100 µg/kg doses of P4pal10. However, a graded reduction was seen with the 1 to 10 µg/kg doses, and 10 µg/kg was the optimally effective dose (Fig. 3A). These hearts had an infarct size of 43 ± 5% of the AAR, which is a 31% reduction in infarct size compared with the control. Heart rate and blood pressures were monitored throughout the procedure, and there were no significant differences between baseline hemodynamics between groups. Mean arterial pressure decreased during ischemia and reperfusion in all groups, but there was no significant difference between groups (data not shown).
|
Clinically, patients generally receive medical treatment for acute myocardial infarction after the onset of symptoms. Thus, we determined whether P4pal10 reduces infarct size when given during ischemia or at reperfusion. Rats were treated with an i.v. bolus of 10 µg/kg P4pal10 15 min after the onset of ischemia or 5 min after initiation of reperfusion. P4pal10 was able to reduce infarct size when administered during ischemia by 21% and at reperfusion by 19% compared with the control (Fig. 3B).
PAR4 Inhibition and Cardioprotection in Vitro. To eliminate the potential role of platelets contributing to the cardioprotective effect of PAR4 inhibition, we studied the effects of tc-Y-NH2 on I/R injury in an isolated heart model. Even though this model is buffer-perfused to wash out blood cells and components, we have recently shown that thrombin is present and active in the isolated heart and thus able to activate PAR4 (Strande et al., 2007). We first performed a concentration-response analysis, using 1, 5, or 10 µM, to determine the optimal protective dose for tc-Y-NH2. It has been shown previously that tc-Y-NH2 acts as a PAR4 antagonist by competing with the binding site of the tethered ligand (Hollenberg and Saifeddine, 2001).
Control hearts produced an infarct size of 51 ± 3% of the AAR (Fig. 4A). Continuous administration of tc-Y-NH2 for 15 min immediately before ischemia resulted in a concentration-dependent reduction of infarct size. Five micromolar tc-Y-NH2 led to the largest reduction in infarct size (25 ± 3%), a 49% decrease. Other concentrations of tc-Y-NH2 had no significant effect on infarct size.
Likewise, tc-Y-NH2 increased recovery of LVDP in a concentration-dependent manner. Again, the optimal concentration was 5 µM (Fig. 4B). There were no differences in hemodynamics at any time points measured between control and tc-Y-NH2-treated groups (data not shown).
The infarct-limiting effect of tc-Y-NH2 was abolished by cotreatment with 20 µM PAR4 AP (49 ± 4%; Fig. 4C). PAR4 AP did not affect infarct size (48 ± 5%) when given alone. Likewise, cotreatment with PAR4 AP also blocked the enhanced recovery of LVDP produced by tc-Y-NH2 (54 ± 4% preischemic LVDP; Fig. 4D) and did not affect LVDP when given alone (52 ± 4%).
P4pal10 was also used to inhibit PAR4 activation in this model. Although we saw a trend favoring a decrease in infarct size, the compound markedly reduced LVDP and coronary flow rate even before ischemia (data not shown). Therefore, we continued to use tc-Y-NH2 (5 µM) instead of P4pal10 for the remaining in vitro studies.
Role of Adenosine in PAR4 Antagonist-Mediated Cardioprotection in Vitro. We considered the possibility of adenosine being a trigger of the infarct-limiting effects observed with PAR4 blockade; therefore, we investigated the role of ARs with the use of 8-SPT (1 µM), a nonspecific antagonist of ARs. Perfusion of hearts with 8-SPT and tc-Y-NH2 for 15 min before ischemia resulted in an infarct size and LVDP similar to the values observed with the control hearts (Fig. 5, A and B). In other words, 8-SPT abolished the cardioprotective effects of tc-Y-NH2. 8-SPT alone did not affect infarct size or LVDP when given alone.
We also investigated whether the cardioprotective effects of direct thrombin inhibition with lepirudin could be abrogated by 8-SPT. We have recently shown that lepirudin decreased I/R injury in rat hearts in vitro (Strande et al., 2007). Perfusion of rat hearts with 8-SPT and lepirudin (1 U/ml) for 15 min before ischemia abolished the protective effects of lepirudin (Fig. 5, C and D). Because adenosine protects the heart by activating survival pathways that include PI3K/Akt, ERK1/2, NOS, and KATP channels, we examined these pathways in PAR4 antagonist-induced cardioprotection.
Role of the PI3K/Akt Pathway in PAR4 Antagonist-Mediated Cardioprotection in Vitro. We used wortmannin, a PI3K inhibitor, to examine the potential role of the PI3K/Akt pathway in mediating the protection after PAR4 inhibition. Wortmannin (100 nM) when given alone had no effect on infarct size or LVDP. However, it abolished the cardioprotective effects of tc-Y-NH2 (Fig. 6, A and B). tc-Y-NH2 had no effect on phosphorylation of Akt before ischemia (data not shown). Akt phosphorylation was increased in the control and tc-Y-NH2-treated groups at reperfusion, but tc-Y-NH2 did not further increase the level of phosphorylation of Akt over the control levels during reperfusion. However, wortmannin significantly decreased Akt phosphorylation at reperfusion (Fig. 6, C and D).
Role of the ERK Pathway in PAR4 Antagonist-Mediated Cardioprotection in Vitro. Isolated hearts were pretreated with the ERK1/2 inhibitor, PD98059 (10 µM), alone or in combination with tc-Y-NH2. PD98059 abrogated the cardioprotective effect of tc-Y-NH2 (Fig. 7, A and B). PD98059 alone had no effect on cardioprotection.
tc-Y-NH2 had no effect on phosphorylation of ERK1/2 before ischemia (data not shown) and did not further increase phosphorylation over control values after reperfusion. PD98059 significantly decreased ERK2 phosphorylation at reperfusion but did not significantly change ERK1 phosphorylation (Fig. 7, C and D).
Role of Nitric-Oxide Synthase in PAR4 Antagonist-Mediated Cardioprotection in Vitro. Blockade of NOS by L-NMA (100 µM) before ischemia had no effect on infarct size or LVDP; however, L-NMA abolished the cardioprotective effect of tc-Y-NH2 (Fig. 8, A and B). Nitric oxide (NO) levels were assessed by measuring tissue nitrite and nitrate levels after 1 h of reperfusion. No differences in nitrite or nitrate levels were detected in the tc-Y-NH2-treated hearts compared with the control hearts, although L-NMA decreased NO levels below control values (data not shown).
Role of KATP Channels in PAR4 Antagonist-Mediated Cardioprotection in Vivo and in Vitro. We examined the role of KATP channels in mediating the cardioprotective effects of both tc-Y-NH2 and P4pal10. Isolated hearts were perfused with the nonselective KATP channel blocker, glibenclamide (3 µM), alone for 15 min or in combination with tc-Y-NH2 for 15 min before ischemia. Glibenclamide completely abolished the cardioprotective effect of tc-Y-NH2 (Fig. 9, A and B). Glibenclamide alone had no effect on infarct size.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Lasley et al., 2007). This is also the first study that has shown cross-talk between PAR4 and adenosine receptors during myocardial ischemia and reperfusion.
PAR4-Adenosine Receptor Cross-Talk. The results of this study clearly suggest there is cross-talk between the thrombin and adenosine signaling pathways in the ischemic-reperfused rat myocardium. However, the basis of receptor cross-talk remains to be elucidated and may be occurring through receptor heterodimerization, G protein uncoupling from the inhibited receptor, distal signal regulation, or the regulation of other receptor agonist release. Adenosine receptors are known to couple with other GPCRs whose activation is required for the infarct-limiting effects of adenosine. In fact, the interaction between adenosine and opioids has been well documented (Peart and Gross, 2003, 2005). Studies have also shown that different GPCRs heterodimerize, resulting in altered ligand-binding properties, modified signaling and trafficking properties (George et al., 2000; Gomes et al., 2001; Minneman, 2007). The different adenosine receptors have also been shown to form heterodimers with other GCPRs such as purinergic receptor P2Y1 and dopamine D1 receptors (Ginés et al., 2000; Yoshioka et al., 2002). In addition, the PARs are known to heterodimerize with other members of their family (Leger et al., 2006; McLaughlin et al., 2007). In theory, PARs may oligomerize with ARs altering signaling of the ARs. For instance, PAR4 inhibition with tc-Y-NH2 may uncouple the AR and allow adenosine signaling, ultimately conferring a cardioprotective action. However, receptor heterodimerization is not likely to explain the cross-talk between PAR4 and AR because direct thrombin inhibition has also been shown to mediate its cardioprotective effects through the AR. Therefore, receptor cross-talk probably occurs further down in the signaling pathway. For instance, thrombin and PAR4 activation may result in signaling pathways that down-regulate adenosine signaling pathways, and the removal of PAR4's signaling pathways may then allow the protective effects of adenosine signaling to take precedence. This is the first report that protection provided by PAR4 inhibition may be mediated by endogenous adenosine in a rat model of myocardial I/R injury.
PI3K/Akt. PI3K/Akt is an important mediator of cardioprotection (Hausenloy et al., 2005). Inhibition of this pathway has been shown to abolish the infarct-limiting effects of several pharmaceuticals (Li and Sato, 2001; Qin et al., 2003). However, thrombin and its receptor PAR4 have both been found to increase phosphorylation of Akt in isolated rat cardiomyocytes (Sabri et al., 2003; Snabaitis et al., 2005), so as confirmed by our results, we did not expect tc-Y-NH2 to up-regulate Akt phosphorylation. Nonetheless, Akt phosphorylation was increased in control and treatment groups at reperfusion and significantly reduced in the wortmannin-treated groups. This indicates that a basal level of activation of Akt is necessary for cardioprotection. This basal level of activation may result from adenosine release at reperfusion and stimulation of its receptors.
In contrast, other studies have questioned the role of PI3K/Akt in adenosine-mediated cardioprotection (Qin et al., 2003; Yang et al., 2004). This is probably due to the different signaling patterns of the various ARs important in cardioprotection. For instance, A1ARs do not depend on activation of PI3K/Akt for their infarct-limiting effects, whereas A2AR and A3AR do signal through this kinase pathway to produce their cardioprotective effects (Germack and Dickenson, 2005). Our data would suggest that the cardioprotective effects of PAR4 inhibition are due to the activation of A2AR and/or A3AR.
ERK1/2. ERK1/2 is also an important mediator of cardioprotection (Hausenloy et al., 2005). ERK1/2 phosphorylation is increased after thrombin or PAR4 AP treatment of isolated rat cardiomyocytes (Sabri et al., 2003; Snabaitis et al., 2005). Therefore, we did not expect tc-Y-NH2 to induce phosphorylation of ERK1/2 as supported by our results. On the other hand, adenosine has been shown to signal through ERK1/2 to produce its infarct-sparing effects (Headrick et al., 2003a). We found that ERK2 phosphorylation was increased at reperfusion in the control and tc-Y-NH2-treated groups but that PD98059 significantly decreased phosphorylation at reperfusion. This would suggest that a basal level of ERK2 activation is necessary for cardioprotection. It is presumed that this basal activation is at least in part caused by adenosine.
NOS. Nitric-oxide synthase produces NO to act as a mediator against myocardial stunning and infarction. Blocking NOS with N
-nitro-L-arginine methyl ester abrogates pharmacological preconditioning with AR agonists in whole hearts (Krieg et al., 2004; Oldenburg et al., 2004). Thrombin and PAR4 activation have been associated with increasing NO production in endothelium and intact vessels (Momota et al., 2006; Touyz, 2007); therefore, it is not surprising that PAR4 inhibition with tc-Y-NH2 did not change NO production over control values. However, L-NMA alone did decrease NO production, indicating that a basal level of NO is required for cardioprotection in this system. Adenosine has been shown to mediate cardioprotection by up-regulating NO production (Headrick et al., 2003a; Yang et al., 2004). It is possible that the basal NO production that is required for cardioprotection is at least in part caused by adenosine receptor activation.
KATP Channels. Activation of KATP channels are both integral triggers and end-effectors of cardioprotection. They are highly expressed in myocardial sarcolemma and thought to be expressed in myocardial mitochondria. Both ischemic and pharmacologic preconditioning are dependent on the opening of these channels (Much-Ellingsen et al., 1996; Peart and Gross, 2002). Furthermore, both sarc and mitoKATP channels have been implicated in adenosine-mediated cardioprotection (Peart and Gross, 2002). The current study describes a role for both sarc and mitoKATP channels in the infarct-limiting effects of the PAR4 antagonist. Blockade of either channel 5 min before reperfusion abolishes the cardioprotective effects of P4pal10, suggesting that the channels are end-effectors of cardioprotection. A similar effect is observed when the KATP channel inhibitors are administered before ischemia. This may suggest that the sarc and mitoKATP channels are also triggers of cardioprotection induced by PAR4 blockade.
Study Limitations. This study is based on the assumption that endogenous adenosine is mediating cardioprotection by acting on its receptors. A limitation of this study is the lack of direct measurement of adenosine concentration in the presence and absence of the PAR4 antagonist. However, increased production of adenosine during myocardial ischemia has been well documented (Sommerschild and Kirkeboen, 2000), and we do not expect tc-Y-NH2 to affect production of adenosine in treated hearts. Moreover, the cardioprotective effects of PAR4 inhibition were verified with two structurally different compounds, and it is unlikely that both of them would have the same effects on endogenous adenosine production. Furthermore, if the levels of endogenous adenosine differed between the control and treated hearts, we would expect a difference in hemodynamic parameters such as a decreased heart rate and increase in coronary flow. We did not observe any differences between the tc-Y-NH2 treatment and control groups in vitro or P4pal10 treatment and control groups in vivo. P4pal10 treatment in vitro did result in a marked reduction of coronary flow in these hearts and was not associated with cardioprotection. It is possible the PAR4 antagonists, tc-Y-NH2 and P4pal10, have effects other than blocking PAR4 signaling. Although these potential effects should be considered, the reversal of the infarct-limiting effects of tc-Y-NH2 at the receptor level with a PAR4 agonist, PAR4 AP, which would compete for the ligand binding site would suggest that the protection seen is indeed due to the blockade of PAR4 coupled with the activation of the AR by endogenous adenosine.
In summary, the data presented demonstrate that inhibition of PAR4 affords marked protection against infarct development in an in vivo and in vitro model of myocardial I/R injury, probably due to activation of ARs by endogenously produced adenosine. The protection observed appears to be dependent upon AR activation, Akt, ERK1/2, and NOS, along with opening of the sarc and mitoKATP channels. Inhibition of PAR4 presents a novel approach to achieve potent adenosine-mediated cardioprotection after production of endogenous adenosine.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: I/R, ischemia/reperfusion; GPCR, G protein-coupled receptor; AR, adenosine receptor; ERK, extracellular signal-regulated kinase; NOS, nitric-oxide synthase; sarc, sarcolemmal; mito, mitochondrial; PAR, protease-activated receptor; AP, activating peptide; tc-Y-NH2, trans-cinnamoyl-YPGKF-amide; P4pal10, palmitoyl-SGRRYGHALR-amide; SD, Sprague-Dawley; PCR, polymerase chain reaction; PD98059, 2'-amino-3'-methoxyflavone; LVDP, left ventricular developed pressure; L-NMA, NG-monomethyl-L-arginine; 8-SPT, 8-sulfaphenyltheophylline; AAR, area at risk; NO, nitric oxide; 5-HD, 5-hydroxydecanoic acid; PI3K, phosphoinositide-3 kinase; HMR 1098, sodium (5-(2-(5-chloro-2-methoxybenzamido)ethyl)-2-methoxyphenylsulfonyl)(methylcarbamothioyl)amide.
Address correspondence to: Dr. Jennifer L. Strande, Division of Cardiovascular Medicine, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226. E-mail: jstrande{at}mcw.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Chong AJ, Pohlman TH, Hampton CR, Shimamoto A, Mackman N, and Verrier ED (2003) Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg 75: S649 –S655.
Covic L, Misra M, Badar J, Singh C, and Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8: 1161–1165.[CrossRef][Medline]
Deguchi H, Takeya H, Urano H, Gabazza EC, Zhou H, and Suzuki K (1998) Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 91: 57–64.[CrossRef][Medline]
D'Hondt C, Srinivas SP, Vereecke J, and Himpens B (2007) Adenosine opposes thrombin-induced inhibition of intercellular calcium wave in corneal endothelial cells. Invest Ophthalmol Vis Sci 48: 1518 –1527.
Dubey RK, Gillespie DG, Mi Z, and Jackson EK (1997) Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 96: 2656 –2666.
George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of µ- and 
-opioid receptors: generation of novel functional properties. J Biol Chem 275: 26128 –26135.
Germack R and Dickenson JM (2005) Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 39: 429–442.[CrossRef][Medline]
Ginés S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, et al. (2000) Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci U S A 97: 8606–8611.
Gomes I, Jordan BA, Gupta A, Rios C, Trapaidze N, and Devi LA (2001) G protein coupled receptor dimerization: implications in modulating receptor function. J Mol Med 79: 226 –242.[CrossRef][Medline]
Hausenloy DJ, Tsang A, and Yellon DM (2005) The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15: 69 –75.[CrossRef][Medline]
Headrick JP, Hack B, and Ashton KJ (2003a) Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 285: H1797–H1818.
Headrick JP, Hack B, and Ashton KJ (2003b) Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 285: H1797–H1818.
Hollenberg MD and Saifeddine M (2001) Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can J Physiol Pharmacol 79: 439–442.[CrossRef][Medline]
Krieg T, Qin Q, Philipp S, Alexeyev MF, Cohen MV, and Downey JM (2004) Acetylcholine and bradykinin trigger preconditioning in the heart through a pathway that includes Akt and NOS. Am J Physiol Heart Circ Physiol 287: H2606 –H2611.
Lasley RD, Kristo G, Keith BJ, and Mentzer RM Jr (2007) The A2a/A2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium. Am J Physiol Heart Circ Physiol 292: H426 –H431.
Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, and Kuliopulos A (2006) Blocking the protease-activated receptor 1–4 heterodimer in platelet-mediated thrombosis. Circulation 113: 1244 –1254.
Li Y and Sato T (2001) Dual signaling via protein kinase C and phosphatidylinositol 3'-kinase/Akt contributes to bradykinin B2 receptor-induced cardioprotection in guinea pig hearts. J Mol Cell Cardiol 33: 2047–2053.[CrossRef][Medline]
Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, et al. (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34: 1711–1720.
McLaughlin JN, Patterson MM, and Malik AB (2007) Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci USA 104: 5662–5667.
Minneman KP (2007) Heterodimerization and surface localization of G protein coupled receptors. Biochem Pharmacol 73: 1043–1050.[CrossRef][Medline]
Momota F, Hirano K, Hirano M, Nishimura J, and Kanaide H (2006) Involvement of Gi/o in the PAR-4-induced NO production in endothelial cells. Biochem Biophys Res Commun 342: 365–371.[CrossRef][Medline]
Much-Ellingsen J, Bugge E, and Ytrehus K (1996) Blockade of the KATP-channel by glibenclamide aggravates ischemic injury, and counteracts ischemic preconditioning. Basic Res Cardiol 91: 382–388.[Medline]
Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, Cohen MV, and Downey JM (2004) Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol 286: H468 –H476.
Ossovskaya VS and Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84: 579–621.
Peart JN and Gross GJ (2002) Sarcolemmal and mitochondrial KATP channels and myocardial ischemic preconditioning. J Cell Mol Med 6: 453–464.[Medline]
Peart JN and Gross GJ (2003) Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol 285: H81–H89.
Peart JN and Gross GJ (2005) Cardioprotection following adenosine kinase inhibition in rat hearts. Basic Res Cardiol 100: 328 –336.[CrossRef][Medline]
Piper HM, Volz A, and Schwartz P (1990) Adult ventricular rat heart muscle cells, in Cell Culture Techniques in Heart and Vessel Research (Piper HM ed) pp 36–60, Springer Verlag, Berlin, Germany.
Qin Q, Downey JM, and Cohen MV (2003) Acetylcholine but not adenosine triggers preconditioning through PI3-kinase and a tyrosine kinase. Am J Physiol Heart Circ Physiol 284: H727–H734.
Rohatgi T, Henrich-Noack P, Sedehizade F, Goertler M, Wallesch CW, Reymann KG, and Reiser G (2004) Transient focal ischemia in rat brain differentially regulates mRNA expression of protease-activated receptors 1 to 4. J Neurosci Res 75: 273–279.[CrossRef][Medline]
Ross AM, Gibbons RJ, Stone GW, Kloner RA, and Alexander RW (2005) A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45: 1775–1780.
Sabri A, Guo J, Elouardighi H, Darrow AL, Andrade-Gordon P, and Steinberg SF (2003) Mechanisms of protease-activated receptor-4 actions in cardiomyocytes: role of Src tyrosine kinase. J Biol Chem 278: 11714 –11720.
Shryock JC and Belardinelli L (1997) Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 79: 2–10.[Medline]
Snabaitis AK, Muntendorf A, Wieland T, and Avkiran M (2005) Regulation of the extracellular signal-regulated kinase pathway in adult myocardium: differential roles of Gq/11, Gi and G12/13 proteins in signalling by [alpha]1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors. Cell Signal 17: 655–664.[CrossRef][Medline]
Sommerschild HT and Kirkeboen KA (2000) Adenosine and cardioprotection during ischaemia and reperfusion: an overview. Acta Anaesthesiol Scand 44: 1038 –1055.[CrossRef][Medline]
Strande JL, Hsu A, Su J, Fu X, Gross GJ, and Baker JE (2007) SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol 102: 350 –358.[CrossRef][Medline]
Touyz RM (2007) Regulation of endothelial nitric oxide synthase by thrombin. Hypertension 49: 429–431.
Yang X-M, Krieg T, Cui L, Downey JM, and Cohen MV (2004) NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36: 411–421.[CrossRef][Medline]
Yellon DM, Alkhulaifi AM, Browne EE, and Pugsley WB (1992) Ischaemic preconditioning limits infarct size in the rat heart. Cardiovasc Res 26: 983–987.
Yoshioka K, Hosoda R, Kuroda Y, and Nakata H (2002) Hetero-oligomerization of adenosine A1 receptors with P2Y1 receptors in rat brains. FEBS Lett 531: 299–303.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  J. L. Strande, M. E. Widlansky, N. E. Tsopanoglou, J. Su, J. Wang, A. Hsu, K. V. Routhu, and J. E. Baker Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury Cardiovasc Res, July 15, 2009; 83(2): 325 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Strande Letter by Strande Regarding Article "Protease-Activated Receptor-1 Contributes to Cardiac Remodeling and Hypertrophy" Circulation, June 17, 2008; 117(24): e495 - e495. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
